Vir Biotechnology, Inc.VIR

Vir Biotechnology Inc. is a clinical-stage immunology company that builds pipeline candidates on antibody expertise, artificial intelligence, and the PRO-XTEN masking platform for oncology and infectious disease; its public pages trumpet immunologic breakthroughs, yet the latest SEC 10-Q shows the group earned just $29,000 in revenue for the quarter to 31 March 2026 and posted a net loss of $125.7 million.

The company’s “Therapeutic Focus” page explains that VIR-7229 is supported in whole or in part with federal funds from the Department of Health and Human Services, signalling that the story is as much about public science budgets as it is about private markets. Vir’s collaborators page lists partnerships with leading scientists, agencies, and non-profits, yet the balance sheet shows liabilities of $212.8 million against $274.2 million of cash-hardly a fortress of working capital for a platform that claims to be powering the immune system’s next act.

Filings detail a pipeline with multiple clinical- and pre-clinical-stage candidates, but the same 10-Q shows operating loss of $132.3 million and EPS (diluted) of minus $0.85. Research and development expense ran to $108.9 million in the quarter, more than three times the revenue collected, and capitalised fixed-asset additions were a rounding error at $390,000. Share count for diluted EPS was 147.4 million shares, unchanged from the prior quarter, so dilution is not masking the loss this time.

The company’s March 2026 10-Q reports total assets of $1.03 billion, of which $671 million is goodwill and intangibles, implying much of the corporate story is still on paper rather than in patients. Vir’s SEC filings remain the only authoritative source for the numbers above, and the group’s own ethics hotline points to an anonymous whistle-blower channel if investors wish to probe governance or conduct.

For colour on the company’s science platforms and collaborators, readers can review the product pages linked from the official site, but these pages are marketing material and do not contain audited financial statements or clinical outcome data. The SEC filings remain the definitive record for performance, cash and risk.

Market context can be tracked on TradingView via the VIR:NASDAQ route, but no valuation commentary, support or resistance levels are implied by this report; the file is strictly research, not advice.